These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 1824955

  • 1. Pituitary and brain D2 receptor density measured in vitro and in vivo in EEDQ treated male rats.
    Ekman A, Eriksson E.
    Life Sci; 1991; 48(4):321-31. PubMed ID: 1824955
    [Abstract] [Full Text] [Related]

  • 2. A high dose of EEDQ reduces pituitary dopamine D2 receptor density and the prolactin suppressive potency of agonists.
    Ekman A, Eriksson E.
    Eur J Pharmacol; 1993 Oct 26; 243(3):295-9. PubMed ID: 7903944
    [Abstract] [Full Text] [Related]

  • 3. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O, Biggio G.
    Brain Res; 1990 Nov 12; 533(1):53-9. PubMed ID: 1982234
    [Abstract] [Full Text] [Related]

  • 4. Effects of the two partial D2 agonists (+)- and (-)-3-PPP on prolactin release in EEDQ treated male rats.
    Ekman A, Quiding M, Eriksson E.
    Life Sci; 1991 Nov 12; 48(4):311-20. PubMed ID: 1671291
    [Abstract] [Full Text] [Related]

  • 5. Dopamine receptor reappearance after irreversible receptor blockade: effect of chronic estradiol treatment of ovariectomized rats.
    Lévesque D, Di Paolo T.
    Mol Pharmacol; 1991 May 12; 39(5):659-65. PubMed ID: 1674586
    [Abstract] [Full Text] [Related]

  • 6. The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.
    Ogren SO, Rosén L, Fuxe K.
    Neuroscience; 1994 Jul 12; 61(2):269-83. PubMed ID: 7969908
    [Abstract] [Full Text] [Related]

  • 7. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine.
    Burger LY, Martin-Iverson MT.
    Synapse; 1993 Jan 12; 13(1):20-9. PubMed ID: 8093985
    [Abstract] [Full Text] [Related]

  • 8. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms.
    Norman AB, Battaglia G, Creese I.
    J Neurosci; 1987 May 12; 7(5):1484-91. PubMed ID: 2952771
    [Abstract] [Full Text] [Related]

  • 9. Effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on the prolactin suppression induced by a series of full and partial dopamine D2 receptor agonists in male rats.
    Ekman A, Eriksson E.
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Aug 12; 346(2):152-7. PubMed ID: 1360151
    [Abstract] [Full Text] [Related]

  • 10. EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors.
    Nowak G, Arnt J, Hyttel J.
    Eur J Pharmacol; 1988 Aug 24; 153(2-3):309-11. PubMed ID: 3053212
    [Abstract] [Full Text] [Related]

  • 11. Effect of aging on recovery of striatal dopamine receptors following N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) blockade.
    Henry JM, Roth GS.
    Life Sci; 1984 Aug 20; 35(8):899-904. PubMed ID: 6482680
    [Abstract] [Full Text] [Related]

  • 12. Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade.
    Pich EM, Benfenati F, Farabegoli C, Fuxe K, Meller E, Aronsson M, Goldstein M, Agnati LF.
    Brain Res; 1987 Dec 01; 435(1-2):147-52. PubMed ID: 2962698
    [Abstract] [Full Text] [Related]

  • 13. In vivo labelling of pituitary dopamine D-2 receptors in the male rat using [3H]-raclopride.
    Köhler C, Karlsson-Boethius G.
    J Neural Transm; 1989 Dec 01; 76(1):13-28. PubMed ID: 2523467
    [Abstract] [Full Text] [Related]

  • 14. Analysis of [3H]spiperone binding sites in the rat striatum and frontoparietal cortex by means of quantitative receptor autoradiography after inactivation of dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by sulpiride in the striatum.
    Fuxe K, Meller E, Goldstein M, Benfenati F, Agnati LF.
    Neurosci Lett; 1986 Feb 28; 64(2):163-8. PubMed ID: 3960398
    [Abstract] [Full Text] [Related]

  • 15. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.
    Xu SX, Hatada Y, Black LE, Creese I, Sibley DR.
    J Pharmacol Exp Ther; 1991 May 28; 257(2):608-15. PubMed ID: 1674530
    [Abstract] [Full Text] [Related]

  • 16. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors.
    Hess EJ, Norman AB, Creese I.
    J Neurosci; 1988 Jul 28; 8(7):2361-70. PubMed ID: 2907912
    [Abstract] [Full Text] [Related]

  • 17. Alterations in the turnover rate of dopamine D1 but not D2 receptors in the adult rat neostriatum after a neonatal dopamine denervation.
    Dewar KM, Paquet M, Reader TA.
    Neurochem Int; 1997 Jun 28; 30(6):613-21. PubMed ID: 9153003
    [Abstract] [Full Text] [Related]

  • 18. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
    Hamblin MW, Creese I.
    Life Sci; 1983 May 09; 32(19):2247-55. PubMed ID: 6133202
    [Abstract] [Full Text] [Related]

  • 19. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study.
    Morissette M, Lévesque D, Di Paolo T.
    Mol Pharmacol; 1992 Sep 09; 42(3):480-8. PubMed ID: 1357544
    [Abstract] [Full Text] [Related]

  • 20. Unilateral inactivation of dopamine receptors after intrastriatal injection of N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): a novel rotational model to investigate dopamine receptor interactions.
    Giorgi O, Biggio G.
    Pharmacol Biochem Behav; 1990 Apr 09; 35(4):877-84. PubMed ID: 1971721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.